AVATAR Extended Follow-up: Long-term results with median 63-month follow-up demonstrated sustained benefits of early intervention in asymptomatic patients with severe aortic stenosis.

EARLY TAVR: This pivotal trial showed that after a median follow-up of 3.8 years, 87% of patients in the conservative management group eventually required TAVI. Importantly, there were no differences in procedure-related adverse events between the early TAVI group and those who underwent delayed intervention, suggesting early TAVI is safe and may prevent disease progression.

EVOLVED: Enrolled 224 of 427 screened patients with asymptomatic severe AS and preserved left ventricular ejection fraction (>50%). The study demonstrated no unplanned aortic valve replacement in the first year, providing insights into the natural history and optimal timing of intervention.

Transcatheter vs Surgical Treatment in Younger Patients

DEDICATE & NOTION-2: These randomized controlled trials addressed a critical gap in evidence by comparing TAVI with surgical AVR in young, low-surgical-risk patients with severe aortic stenosis. NOTION-2 specifically included both tricuspid and bicuspid aortic valve stenosis patients, expanding the evidence base for TAVI in anatomically complex cases and younger populations.

Moderate Aortic Stenosis with Heart Failure

TAVI-UNLOAD: This trial aimed to determine whether TAVI complemented guideline-directed medical therapy (GDMT) in patients with concomitant moderate AS and heart failure. The study was prematurely stopped after enrolling 178 patients (mean age 77 years, 56% in NYHA class III or IV). While TAVI was associated with better quality of life, it was not superior to surveillance for hard clinical endpoints, challenging the concept of earlier intervention in moderate AS.

Secondary Mitral Regurgitation 

RESHAPE 2: This trial evaluated transcatheter edge-to-edge repair in ventricular secondary mitral regurgitation. Although formally a positive trial, there was no difference in all-cause mortality, cardiovascular mortality, or overall hospitalizations between intervention and medical therapy groups. The primary benefit appeared to be in symptom improvement rather than survival.

Tricuspid Regurgitation Treatment

TRI-FR: This study examined whether transcatheter edge-to-edge repair (T-TEER) combined with optimized medical therapy improved outcomes compared with OMT alone in severe, symptomatic TR. Results showed no difference in survival or major cardiovascular events, with positive results mainly driven by improved patient-reported outcome measures.

TRISCEND II: Evaluated transcatheter tricuspid valve replacement (TTVR). The intervention group experienced higher 30-day cardiovascular mortality (3.1% vs 0%), severe bleeding in 10.4% of patients, and 24.7% required new permanent pacemaker or defibrillator implantation. The study lacked a sham-controlled arm, limiting interpretation.

 TRIGISTRY/TRI-SCORE: This registry-based analysis with surgical risk stratification revealed that low-risk TRI-SCORE patients showed clear survival advantage with surgery or transcatheter repair. Intermediate-risk patients benefited only with successful interventions, particularly surgical repair. High-risk patients showed no clear survival benefit from intervention, suggesting conservative management may be appropriate.

 Key ESC 2025 Guideline Updates

• Lower TAVI Age Threshold: Reduced from 75 to 70 years, expanding access to less invasive treatment
• Enhanced Tricuspid Treatment: Upgraded to class II-A recommendation based on randomized trial data showing improved quality of life and reduced heart failure hospitalizations
• Bicuspid AS: TAVI now considered for symptomatic patients with bicuspid AS at increased surgical risk (IIB)
• Sex-Specific Considerations: New recommendations addressing treatment differences for women across aortic, mitral, and tricuspid valve diseases
• Mechanical Valves: Class IIa recommendation for patients with long life expectancy